Reuters logo
BRIEF-Biondvax Pharmaceuticals: trial meets both primary endpoints
July 20, 2017 / 11:00 AM / 3 months ago

BRIEF-Biondvax Pharmaceuticals: trial meets both primary endpoints

July 20 (Reuters) - Biondvax Pharmaceuticals Ltd

* Biondvax reports positive Phase 2b clinical trial results for its universal flu vaccine

* Biondvax Pharmaceuticals Ltd says trial meets both primary endpoints

* Biondvax Pharmaceuticals Ltd- ‍statistically significant positive results from Phase 2b clinical trial of M-001​

* Biondvax Pharmaceuticals - in one of four H5N1 strains tested, a statistically significant HAI elevation was observed in participants who had received M-001

* Biondvax Pharmaceuticals Ltd- ‍confirms that M-001 has a good safety profile and is well-tolerated​

* Biondvax-Considering taking opportunity to proceed directly to testing clinical efficacy of vaccination with M-001 alone in pivotal Phase 3 clinical trial​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below